Jessica Serra | Head, IR & ESG |
Mark Foley | CEO & Director |
Dustin Sjuts | President |
Tobin Schilke | CFO & Principal Accounting Officer |
Seamus Fernandez | Guggenheim Securities |
David Amsellem | Piper Sandler & Co. |
Chris Shibutani | Goldman Sachs Group |
Stacy Ku | TD Cowen |
Timothy Lugo | William Blair & Company |
Balaji Prasad | Barclays Bank |
Annabel Samimy | Stifel, Nicolaus & Company |
Navann Dietschi | BNP Paribas Exane |
Douglas Tsao | H.C. Wainwright & Co. |
Terence Flynn | Morgan Stanley |
Charles Uy | Mizuho |
Welcome to the Revance Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions].
As a reminder, this call is being recorded today, Tuesday, August 8, 2023. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Communications and ESG for Revance.